GI 스텐트 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

GI Stent Market

The future of the global gi stent market looks promising with opportunities in the hospital, ambulatory surgical center, and specialty clinic markets. The global gi stent market is expected to reach an estimated $1000 million by 2035 from $679 million in 2027 with a CAGR of 5.1% from 2027 to 2035. The major drivers for this market are the increasing prevalence of gastrointestinal disorders, the rising demand for minimally invasive treatments, and the growing adoption of advanced stent technologies.

• Lucintel forecasts that, within the product type category, biliary stents is expected to witness the highest growth over the forecast period due to the need for more minimally-invasive treatment for increasing biliary obstruction.
• Within the end use category, hospitals is expected to witness the highest growth over the forecast period due to the high volume of gastrointestinal procedures performed in hospitals.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the high level of advanced healthcare infrastructure in the region.

Emerging Trends in GI Stent Market

Trends are shifting toward drug-eluting stents over existing platforms with an emphasis on advanced design to prevent restenosis and treated for more advanced cases and bifurcation stenting. From 2025-2027, hospitals will select devices based on efficacy, shorter hospital stays, and quicker catheterization procedures. Lucintel predicts the future based on demographic shifts, changes in reimbursement, and innovation.

• Drug-eluting Stents: Manufacturers are thinner strut and coating drug-eluting stents and reducing drug doses. The Synergy drug-eluting stent platform (reported in September 2025) by Boston Scientific reports a 74% reduced target lesion failure at 5 years. This trend will allow for premium pricing as physicians obtain durable outcomes.
• Complex-lesion Treatment: The shifting focus of clinical trials toward treating long lesions, small vessels, chronic total occlusions, and bifurcations; 2025 registries documented procedures using stents longer than 40 mm.
• Bioabsorbable Stents: Research stents that offer scaffold support will continue as a focus of research with many studies following patients up to 36 months. There are many design concerns, but successful designs will eliminate the risk of a permanent foreign body and allow for use in an expanding population.
• Image-guided Procedures: Specialist preference for intravascular ultrasound and optical coherence tomography is moving to protocol-driven. 2025 studies show imaging-guided PCI can potentially reduce adverse cardiovascular events by approximately 25%. The increased use of imaging will help with sizing, placement, and post-placement assessment.
• Regional Supply Diversification: During the pandemic, hospital disruptions resulted in companies striving to build dual-source manufacturing and local regulatory functions to give clients stable supply. By 2025, India's medical device manufacturing reached a target of ₹29,000 crore. By 2030, diversified supply chains will lead to shorter lead times and increased price competition.

The market will value clinical performance over unit volume for the first time. Change will come as drug-eluting systems mature and differentiate high-value services from low-cost suppliers. Hospitals will look at the total cost of ownership, and manufacturers will need to show continued safety of the systems, ease of delivery, and assured supply as demand for the services grows.

Recent Developments in the GI Stent Market

GI stent market activity is expected to accelerate from 2025 to 2027 as manufacturers aim to develop minimally invasive drainage systems and under-developed delivery systems and designs. According to Lucintel, there should be a gradual acceptance of the technology. From a purchasing perspective, however, the release of reimbursement and evidence for clinical use of the technology still has considerable sway.

• Technology Launches: In March 2025, Boston Scientific's AXIOS platform expansion created interest in lumen-apposing metal stents for endoscopic drainage. Expectations over the next three to five years point to a shift toward the demand for faster, single-session procedures.
• Strategic Collaborations: In June 2025, Olympus and hospital-based research partners increased their clinical focus on disposable endoscopy and stent placement. Evidence-based approaches should encourage the adoption of gastroenterology department work-based collaborations.
• Production Expansion: In August 2025, Taewoong Medical responded to demand for covered and uncovered biliary stents by increasing production capacity by 20%. This has reduced the risk of increased lead-time and has increased competition for the offering of biliary stents in emerging markets.
• Government Approvals: In 2025, there were 510(k) clearances for newer self-expanding metal stents. Faster approvals should broaden the range of options available to physicians. Post-marketing evidence will differentiate durable products from low value substitutes.
• Major Contracts: Throughout 2026, major contracts included a 12 site contract that was signed in February. Contract Purchasing will consolidate orders among suppliers as contracts focus on clinically supportable, reliable inventory and training.

It is expected that growth in the gi stent market will be driven mainly by the number of procedures, rather than volume. Reliable demand will come from biliary and colorectal stents. Higher growth potential lies in pancreatic drainage. Clinical evidence, broad regulatory control, and consistent, reliable distribution will enable vendors to gain market share. Hospital customers will place greater value on systems that result in lower total cost of procedures, especially if such systems decrease the number (and length) of procedures required. There will be strong competitive pressure on prices for all stent systems. However, a slight premium will be sustainably charged for stent systems that improve outcomes. Over the next 5 years, the main competitive advantage in this market will be not just the availability of GI stents, but the improvement in the delivery of, removing, and controlling the complications of the stents.

Strategic Growth Opportunities in the GI Stent Market

The Funding Potential for The Gastrointestinal Stent Market is Expected To Grow with The Increase in Incidence of Cancer, Expansion of Minimally Invasive Practices, and Pressure on Healthcare Institutions for Shorter Lengths of Stay. Lucintel's Analysis Cites as The Most Disruptive and Lucrative Strategies: Diversification of vended devices, wider scope of indication, and the penetration of underdiagnosed markets facilitated by distribution partners.

• Benign Strictures: Fully covered and drug-eluting metal stents are currently indicated for use in benign strictures, and a multi-center study in March 2025 reported an 86% clinical success rate. As alternatives to multiple invasive dilation procedures or surgery, it is anticipated that this segment will also grow.
• Oncology Palliation: The rising incidence of gastrointestinal cancers creates a demand for stents that mitigate dysphagia, jaundice, and obstruction, with a lower requirement for subsequent interventions. The American Cancer Society reports an estimated 156,000 cases of colorectal cancer in the USA for 2025. It is anticipated that, within the next 3 to 5 years, better delivery systems will facilitate acquisition of stents from oncology networks.
• Biodegradable Stents: With planned removal of the stent, there may be a future revenue stream where there is a clinical and economic burden. In February 2025, a European study reported biodegradable oesophageal stents follow-up at more than 12 months. Regulatory clearances may potentially shift a market preference to temporary stent devices and higher prices.
• Expanding Into Emerging Markets: Access and reimbursement challenges make India, Southeast Asia, Latin America, and the Middle East underdeveloped. In April 2025, the National Health Authority of India reported that over 750 million Indians had access to public health coverage. More local training and pricing at different levels will incentivize providers to perform a greater volume of procedures.
• Customized Stent Systems: Complex anatomy provides the opportunity to have higher margins with customized stents that include patient-specific sizing and anti-migration and customized delivery systems. In January 2026, a European manufacturer launched a system that allows for more than 20 options for diameter and length. In the area of new stent designs, hospitals will consider purchasing based on how successful the first procedure is and the cost of subsequent procedures.

Clinical distinction rather than overall volume will be what defines the next phase of growth in the market. Pricing will become more competitive as differentiated offerings become more clinically meaningful and simplify deployment. Forming partnerships with oncology centers and regional distributors will aid market penetration. Biodegradable and customized stent offerings will further segment the market.

GI Stent Market Drivers and Challenges

The gastrointestinal stent market is significantly impacted by changes in technology, changes in the economics of health care, and regulatory changes. This is coupled with the demand for less invasive therapies. Achieving growth is further supported by the prevalence of gastrointestinal diseases, the advancement of clinical evidence, and improved access to hospitals. Constraints to growth include the pressures on reimbursement, the risks of the procedure, the regulatory environment, and the disparities in the healthcare system and the infrastructure. Lucintel views these as the key drivers of competition for long-term market penetration of gastrointestinal stents across hospitals, specialty clinics, and outpatient services.

The factors responsible for driving this market include:

• Increase in The Incidence of Disease: The greater incidence of cancer of the gastrointestinal tract, biliary obstruction, dysphagia, and intestinal dysmotility is a greater indication for the employment of stents. There are also greater numbers of older people and improved screening. In January 2025, the World Health Organization reported that cancer is a significant burden on world health, with colorectal cancer being one of the more prevalent forms of the disease. In the coming years of 2020-2025, more patients will require the management of obstructions or the maintenance of lumen patency with the performance of less invasive procedures.
• Technological Innovation: Implants such as drug-eluting stents that reduce the chances of stent failure and build-up, are biodegradable, fully covered to prevent stent fractures and migration, as well as new anti-migration stent technologies continue to improve. More advanced imaging, endoscopic, and delivery systems allow doctors to offer treatment to anatomically complex patients with fewer cumulative procedures. In March 2025, additional studies were launched to measure the effectiveness of biodegradable and fully covered stents in the reduction of long-term adverse events. These advances will influence the marketplace in the next 3 to 5 years, because physicians will prefer to substitute legacy technologies with more versatile, advanced devices that can be removed and which yield better patient outcomes.
• Preference for Minimally Invasive Care: More and more patients and health care professionals prefer endoscopic treatments over open surgical procedures because such treatments result in shorter hospital stays, lower trauma, and faster recovery. Rapidly advancing endoscopic technology will continue to expand the range of stent placement for complex cases. In June 2025, healthcare systems around the world continued increasing the number of outpatient and short-stay endoscopic procedures. This will drive market growth in the next 3 to 5 years by increasing the number of procedures and extending the use of endoscopic treatments in more healthcare facilities.
• Further Developments Infrastructure: Increased building of specialized tertiary hospitals, cancer centers, endoscopy units, and training for subspecialties has developed the ability for more people to access GI stenting throughout new regions. Building of imaging equipment and interventional GI units also helps physicians perform more advanced procedures. In 2025, the building of healthcare infrastructure throughout many Asian and Middle Eastern countries continued to be a focus. This advanced level of endoscopy will influence the industry during the next three to five years as it bridges the treatment gap and creates new market opportunities in the North American and European regions.
• Enhanced Production: Manufacturing advancements such as material engineering, precision molding, automation of catheters, and optimization of supply chains have resulted in a consistent production of higher quality stents at lower costs. This also enhances availability for a range of new user features. In 2026, there was a continual focus of automated quality control systems in the manufacturing of devices that assess multiple elements of a device as it is built. During the next three to five years, lower variability in production and greater scalability will help companies meet market demand for lower prices, more new devices, and quicker innovation.

The challenges facing this market include:

• Procedural Risks: There are numerous complications that can arise following the procedures including migration, tissue ingrowth, stent perforation, stent thrombosis, stent occlusion and fracture that can necessitate additional procedures and add risk to clinical management. There are potential risks to clinicians when selecting devices for longer and more complex procedures or when they are unable to provide extensive post-procedure monitoring. In April of 2025, published clinical evaluations advocated for the monitoring of adverse events and personalized stent selection for all gastrointestinal interventions. In the next three to five years, this Market challenge is expected to drive demand for more confirmation, less risk designs, ease of retrieval, and more post-procedure monitoring.
• Reimbursement and Cost: There is great variation in how hospital systems are able to cover procedures and how reimbursement is geographically distributed in line with the indication and care setting. Even if a stent may offer an important clinical advantage, purchasing may remain resistant to the use of a drug eluting or a more advanced covered stent system if the budgetary impact has not been sufficiently described. In October 2025, health care systems increasingly relied on value-based procurement and cost-effectiveness analyses to evaluate advanced medical devices. In the next three to five years, this Market challenge is expected to place a premium value on products that demonstrate clinically important measures to decrease the risk of complications, reduce the length and cost of treatment, and decrease the number of procedures needed to treat the condition.
• Regulatory and Clinical Evidence Requirements: Manufacturers face high barriers for biocompatibility, sterility, mechanical performance, cybersecurity (where applicable), and clinical safety. Approving novel devices can be time-intensive. In July (Month) 2025, more demanding post-market surveillance was expected by regulators for implantable medical devices, and this will affect the market in the next 3-5 years. Challenges will increase costs and extend market entry times, but companies focused on building strong clinical evidence and quality systems will cruise through regulatory reporting.

The main drivers for the growth of the gi stent market are the high prevalence of diseases, the preference for minimally invasive procedures, constant innovations, and the improvement of the healthcare infrastructure. Product performance and affordability will improve with advanced materials and manufacturing. There are many factors that will slow market growth, such as clinical complications, low reimbursement, and high regulatory hurdles. The market leaders in the next 3-5 years will be able to present strong clinical evidence, make safer designs, and have improved manufacturing. Overall, progress will depend on a balance of factors such as innovation, affordability, reliability, and outcomes.

List of GI Stent Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies gi stent market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gi stent market companies profiled in this report include-

• Boston Scientific Corporation
• Cook Medical
• C.R. Bard, Inc.
• ELLA-CS, s.r.o.
• Taewoong Medical Co., Ltd.
• Olympus Corporation
• Becton, Dickinson and Company
• Merit Medical Systems, Inc.
• M.I. Tech Co., Ltd.
• ConMed Corporation

GI Stent Market by Segment

The study includes a forecast for the global gi stent market by product type, material, end use, and region.

GI Stent Market by Product Type [Value ($M) from 2019 to 2035]:

• Biliary Stents
• Esophageal Stents
• Duodenal Stents
• Colonic Stents

GI Stent Market by Material [Value ($M) from 2019 to 2035]:

• Metal Stents
• Plastic Stents

GI Stent Market by End Use [Value ($M) from 2019 to 2035]:

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

GI Stent Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the GI Stent Market

The gastrointestinal stent market will be dominated by regulatory clearances, localized manufacturing, and hospital capacity investments until approximately 2027. According to Lucintel's latest research, within supplier strategies, focus on minimally invasive delivery systems has been next to public procurement and trade policies in the major healthcare economies.

• United States: Boston Scientific's R$4.7 billion fourth-quarter 2024 sales reported in February 2025, shows commitment to continued investment across interventional platforms that comprise gastrointestinal devices. This means that with the expansion of investment across the activity, clinical stakeholder investment training can be better oriented to improve and establish the use of gastrointestinal, biliary and esophageal stents across various hospital hospitals in the next 3 to 5 years.
• China: The National Medical Products Administration's 2,806 Class III medical device approvals in 2024 (reported in January 2025) has been used as a local regulatory pathway to expand endoscopic devices by domestic manufacturers. The increase in domestic regulatory approval combined with local procurement should improve access to a variety of competitively priced gastrointestinal stents in Chinese hospitals.
• Germany: Olympus's ¥997.3 billion fiscal-year 2025 sales reported in May 2025, was used to continue investment across its gastrointestinal endoscopy and therapy stent system instrument portfolio. This means that with Germany's clinical research and manufacturing focus, supplier partnerships will be influenced in a positive manner.
• India: The Department of Pharmaceuticals continues the implementation of the National Medical Devices Policy, approved in 2023, while the government's medical-device parks program builds a common manufacturing infrastructure. By February 2025, three parks had been approved. This is significant because domestic production of gastrointestinal stents can be strengthened through shared facilities and the import-substitution policy.
• Japan: In its April 2024 fee revision, the Ministry of Health, Labour and Welfare set national reimbursement prices that included payments for endoscopic procedures involving therapeutic devices. The next scheduled revision is planned for April 2026. This is significant because reimbursement directly influences hospital purchasing as well as volume of procedures and the overall economic sustainability of new gastrointestinal stent systems.

Features of the Global GI Stent Market

• Market Size Estimates: gi stent market size estimation in terms of value ($M).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: gi stent market size by product type, material, end use, and region in terms of value ($M).
• Regional Analysis: gi stent market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different product types, materials, end uses, and regions for the gi stent market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gi stent market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the gi stent market by product type (biliary stents, esophageal stents, duodenal stents, and colonic stents), material (metal stents and plastic stents), end use (hospitals, ambulatory surgical centers, and specialty clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global GI Stent Market by Product Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Product Type
• 4.3 Biliary Stents : Trends and Forecast 2019 to 2035
• 4.4 Esophageal Stents : Trends and Forecast 2019 to 2035
• 4.5 Duodenal Stents : Trends and Forecast 2019 to 2035
• 4.6 Colonic Stents : Trends and Forecast 2019 to 2035

5. Global GI Stent Market by Material

• 5.1 Overview
• 5.2 Attractiveness Analysis by Material
• 5.3 Metal Stents : Trends and Forecast 2019 to 2035
• 5.4 Plastic Stents : Trends and Forecast 2019 to 2035

6. Global GI Stent Market by End Use

• 6.1 Overview
• 6.2 Attractiveness Analysis by End Use
• 6.3 Hospitals : Trends and Forecast 2019 to 2035
• 6.4 Ambulatory Surgical Centers : Trends and Forecast 2019 to 2035
• 6.5 Specialty Clinics : Trends and Forecast 2019 to 2035

7. Regional Analysis

• 7.1 Overview
• 7.2 Global GI Stent Market by Region

8. North American GI Stent Market

• 8.1 Overview
• 8.2 North American GI Stent Market by Product Type
• 8.3 North American GI Stent Market by End Use
• 8.4 The United States GI Stent Market
• 8.5 Canadian GI Stent Market
• 8.6 Mexican GI Stent Market

9. European GI Stent Market

• 9.1 Overview
• 9.2 European GI Stent Market by Product Type
• 9.3 European GI Stent Market by End Use
• 9.4 German GI Stent Market
• 9.5 French GI Stent Market
• 9.6 Italian GI Stent Market
• 9.7 Spanish GI Stent Market
• 9.8 The United Kingdom GI Stent Market

10. APAC GI Stent Market

• 10.1 Overview
• 10.2 APAC GI Stent Market by Product Type
• 10.3 APAC GI Stent Market by End Use
• 10.4 Chinese GI Stent Market
• 10.5 Indian GI Stent Market
• 10.6 Japanese GI Stent Market
• 10.7 South Korean GI Stent Market
• 10.8 Indonesian GI Stent Market

11. ROW GI Stent Market

• 11.1 Overview
• 11.2 ROW GI Stent Market by Product Type
• 11.3 ROW GI Stent Market by End Use
• 11.4 Middle Eastern GI Stent Market
• 11.5 South American GI Stent Market
• 11.6 African GI Stent Market

12. Competitor Analysis

• 12.1 Product Portfolio Analysis
• 12.2 Operational Integration
• 12.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

• 13.1 Value Chain Analysis
• 13.2 Growth Opportunity Analysis
  • 13.2.1 Growth Opportunity by Product Type
  • 13.2.2 Growth Opportunity by Material
  • 13.2.3 Growth Opportunity by End Use
• 13.3 Emerging Trends in the Global GI Stent Market
• 13.4 Strategic Analysis
  • 13.4.1 New Product Development
  • 13.4.2 Certification and Licensing
  • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

• 14.1 Competitive Analysis Overview
• 14.2 Boston Scientific Corporation
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.3 Cook Medical
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.4 C.R. Bard, Inc.
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.5 ELLA-CS, s.r.o.
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.6 Taewoong Medical Co., Ltd.
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.7 Olympus Corporation
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.8 Becton, Dickinson and Company
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.9 Merit Medical Systems, Inc.
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.10 M.I. Tech Co., Ltd.
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.11 ConMed Corporation
  • Company Overview
  • GI Stent Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

15. Appendix

• 15.1 List of Figures
• 15.2 List of Tables
• 15.3 Research Methodology
• 15.4 Disclaimer
• 15.5 Copyright
• 15.6 Abbreviations and Technical Units
• 15.7 About Us
• 15.8 Contact Us